Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation.

Autor: Panneer Selvam S; Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA., De Palma RM; Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA., Oaks JJ; Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA., Oleinik N; Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA., Peterson YK; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA. Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA., Stahelin RV; Department of Biochemistry and Molecular Biology, Indiana University School of Medicine-South Bend, South Bend, IN 46617, USA. Department of Chemistry and Biochemistry and the Mike and Josie Harper Cancer Research Institute, University of Notre Dame, South Bend, IN 46556, USA., Skordalakes E; Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA 19104, USA., Ponnusamy S; Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA., Garrett-Mayer E; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA., Smith CD; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA. Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA., Ogretmen B; Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA. Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA. ogretmen@musc.edu.

Publikováno v: Science signaling [Sci Signal] 2015 Jun 16; Vol. 8 (381), pp. ra58. Date of Electronic Publication: 2015 Jun 16.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Autor: Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2013 Oct; Vol. 123 (10), pp. 4144-57. Date of Electronic Publication: 2013 Sep 03.

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

Autor: Oaks JJ; Human Cancer Genetics Program, Department of Molecular Virology Immunology and Medical Genetics., Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, Arlinghaus RB, Quintas-Cardama A, Goldman JM, Apperley J, Reid A, Milojkovic D, Ziolo MT, Marcucci G, Ogretmen B, Neviani P, Perrotti D

Publikováno v: Blood [Blood] 2013 Sep 12; Vol. 122 (11), pp. 1923-34. Date of Electronic Publication: 2013 Aug 07.

miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.

Autor: Eiring AM; Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA., Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Liebhaber SA, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D

Publikováno v: Cell [Cell] 2010 Mar 05; Vol. 140 (5), pp. 652-65.

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Autor: Neviani P; Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio, USA., Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2007 Sep; Vol. 117 (9), pp. 2408-21.